|Bid||32.21 x 200|
|Ask||47.69 x 100|
|Day's Range||39.02 - 40.74|
|52 Week Range||11.30 - 45.85|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2018 - May 11, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||61.88|
NEW YORK, NY / ACCESSWIRE / April 18, 2018 / Markets continued to rise on Tuesday as investor focus continues to shift from geopolitical concerns to strong corporate earnings from major U.S. companies. ...
Arena Pharmaceuticals (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SAN DIEGO, April 12, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that data from a post-hoc analysis of the 22-week Phase 2 clinical study for its investigative drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH), will be presented at the International Society for Heart and Lung Transplantation (ISHLT) 2018 Annual Meeting on April 14. Dr. Raymond Benza, Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, will present the results of an analysis assessing the impact of ralinepag treatment on mortality risk, as measured by three risk scoring methodologies (REVEAL, FPHN and COMPERA), in patients on PAH specific background therapy.
- Cardiology interventions and diagnostics are a big market, and the new field of remote monitoring, for arrhythmias and heart trouble, is a rapidly expanding component. Better remote monitoring technology ...
Arena Pharmaceuticals Inc’s (NASDAQ:ARNA) announced its latest earnings update in December 2017, which indicated that losses became smaller relative to the prrior year’s level – great news for investors Below,Read More...
SAN DIEGO, March 26, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced the completion of its previously announced underwritten public offering of 9,775,000 shares of its common stock at a price to the public of $41.50 per share, including 1,275,000 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares. All of the shares were sold by Arena. Arena anticipates using the net proceeds from the offering for the clinical and preclinical development of drug candidates, including its planned Phase 3 programs for etrasimod for the treatment of ulcerative colitis and ralinepag for the treatment of pulmonary arterial hypertension, for general corporate purposes, including working capital and costs associated with manufacturing services, and for capital expenditures.
SAN DIEGO , March 23, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, will present a corporate ...
SAN DIEGO, March 21, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced the pricing of an underwritten public offering of 8,500,000 shares of its common stock at a price to the public of $41.50 per share. All of the shares are being sold by Arena. In addition, Arena has granted the underwriters a 30-day option to purchase up to 1,275,000 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.
The biotech sector was in focus last week with Alexion gaining on positive data on PNH candidate, Arena surges on ulcerative drug data, Solid Biosciences' stock suffering a crash and Prothena teaming up with Celgene.
NEW YORK, NY / ACCESSWIRE / March 21, 2018 / Stock markets rallied Tuesday on gains from the energy and consumer discretionary sector. Wall Street appears to be eagerly awaiting details from the Federal ...
Arena Pharmaceuticals Inc. ticked lower Tuesday after the biotech company announced a secondary offering of shares. Arena shares declined 1.9% after hours, following a surge of 29% to close the regular ...
Arena gapped up by nearly a third Tuesday after its ulcerative colitis drug proved strong in a Phase 2 trial.
SAN DIEGO, March 20, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that it intends to offer and sell, subject to market and other conditions, 7,500,000 shares of its common stock in an underwritten public offering. Arena expects to grant the underwriters an option to purchase up to an additional 1,125,000 shares of its common stock. All of the shares are being offered by Arena.